The GLP-1 CVD outcome trials a) Elixa (Lexisenatide) b) Leader (Liraglutide) c) Sustain-6 (Semaglutide) d) Exscel (Weekly Exenatide) e) Harmony (Albiglutide) f) Rewind (Dulaglutide) g) Pioneer 6 (Oral Semaglutide) Elixa Study (Evaluation of Lixisenatide) In ELIXA, the investigational GLP-1 receptor agonist, lixisenatide, neither reduced nor increased cardiovascular events compared with placebo
Esta bradiarritmia afecta a aproximadamente 2% de los fetos de madres con anticuerpos anti-Ro o anti-La, independientemente de los sntomas reumatolgicos maternos
This discovery has sparked considerable scientific interest in whether GLP-1 receptor agonists might offer neuroprotective benefits beyond their established metabolic effects, particularly in conditions such as Parkinson's disease
Several approaches merit further discussion
However, given that this is the first pilot study to explore the clinical utility of serum GPX-3 concentration in patients with AAV, we believe that this study has clinical implications in that this identified a novel biomarker that can assess and estimate activity and damage caused by AAV at diagnosis, although confined to the time of diagnosis
